Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247406 | 0.83 | HRH3 (0.37) | ALDH1A1SIGMAR1POLBCYP2D6L3MBTL1 | |
| SCHEMBL7352978 | 0.80 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1SIGMAR1POLBCYP2D6 | |
| SCHEMBL950379 | 0.72 | ALDH1A1 (0.39) | KEAP1SMN1; SMN2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL585804 | 0.70 | ALDH1A1 (0.38) | KEAP1SMN1; SMN2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL235080 | 0.69 | KDM4E (0.65) | KEAP1SMN1; SMN2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL19732396 | 0.68 | FLT3 (0.49) | SMN1; SMN2KDM4EALDH1A1SIGMAR1FLT3 | |
| SCHEMBL10913328 | 0.67 | KDM4E (0.70) | KEAP1SMN1; SMN2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL11856358 | 0.67 | KDM4E (0.70) | KEAP1SMN1; SMN2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL2821691 | 0.67 | — | — | |
| SCHEMBL3258076 | 0.67 | LMNA (0.38) | KDM4EALDH1A1SIGMAR1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160106711-A1 | 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-21 | — | — | US | claimed |
| WO-2014047437-A1 | 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-03-27 | — | — | WO | claimed |
| US-5446037-A | Antiallergens; elastase inhibitors | SYNPHAR LABORATORIES, INC. (CA) | 1995-08-29 | — | — | US | claimed |
| US-20160106711-A1 | 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-21 | — | — | US | disclosed |
| WO-2014047437-A1 | 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-03-27 | — | — | WO | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-5446037-A | Antiallergens; elastase inhibitors | SYNPHAR LABORATORIES, INC. (CA) | 1995-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | KEAP1 422/4885SMN1; SMN2 1178/4885KDM4E 1778/4885 |
| US-20160106711-A1 | 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation | RIOX2, EIF4A3, RPL35 | KEAP1 2385/4885SMN1; SMN2 1522/4885KDM4E 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.